# åˆ¶è¯æ—¥æŠ¥ Pharma Daily

**æ—¥æœŸ**: 2026-02-04
**æ›´æ–°æ—¶é—´**: 2026-02-05 04:14
**æ–°é—»æ•°é‡**: 106

---

## ä»Šæ—¥æ¦‚è§ˆ

## ğŸ“Š AI æ™ºèƒ½åˆ†æ

### ä»Šæ—¥æ¦‚è§ˆ

ä»Šæ—¥è¡Œä¸šåŠ¨æ€èšç„¦äºç›‘ç®¡æ”¿ç­–ä¸é‡ç£…è¯ç‰©å¸‚åœºè¡¨ç°ã€‚FDAç½•è§å„¿ç§‘ç–¾ç—…ä¼˜å…ˆå®¡è¯„åˆ¸è®¡åˆ’é‡æ–°æˆæƒè‡³2029å¹´ï¼Œä¸ºå„¿ç§‘æ–°è¯ç ”å‘æ³¨å…¥å¼ºå¿ƒå‰‚ï¼›ç¤¼å±±ï¼ˆEli Lillyï¼‰GLP-1è¯ç‰©é”€å”®é¢„æœŸå¼ºåŠ²ï¼Œå°½ç®¡é¢ä¸´å®šä»·å‹åŠ›ï¼›å®‰è¿›ï¼ˆAmgenï¼‰ç½•è§ç—…è¯ç‰©Tavneosé¢ä¸´FDAæ’¤å¸‚è¦æ±‚ä½†å…¬å¸æ‹’ç»æ‰§è¡Œï¼Œå‡¸æ˜¾ç›‘ç®¡åšå¼ˆã€‚

### ğŸ”¥ é‡ç‚¹æ–°é—»

**1. FDAâ€™s rare pediatric disease voucher program revived by 2026 government funding bill** â­â­â­â­â­
   - ç±»åˆ«: æ”¿ç­–æ³•è§„
   - ç½•è§å„¿ç§‘ç–¾ç—…ä¼˜å…ˆå®¡è¯„åˆ¸è®¡åˆ’é‡æ–°æˆæƒè‡³2029å¹´ï¼Œå°†æ˜¾è‘—æ¿€åŠ±å„¿ç§‘ç½•è§ç—…è¯ç‰©ç ”å‘ã€‚

**11. Even with pricing headwinds, Eli Lilly expects sales surge to continue in 2026** â­â­â­â­â­
   - ç±»åˆ«: å¸‚åœºåˆ†æ
   - ç¤¼å±±GLP-1è¯ç‰©Mounjaroå’ŒZepboundé”€å”®é¢„æœŸå¼ºåŠ²ï¼Œæ˜¯å½“å‰åˆ¶è¯å¸‚åœºæœ€å¤§å¢é•¿å¼•æ“ã€‚

**28. FDA seeks withdrawal of Amgen's Tavneos, but company says it won't pull drug** â­â­â­â­
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹
   - FDAè¦æ±‚æ’¤å¸‚ä½†å®‰è¿›æ‹’ç»ï¼Œæ¶‰åŠç½•è§ç—…è¯ç‰©å®‰å…¨æ€§ä¸ç›‘ç®¡æƒå¨çš„ç½•è§å…¬å¼€å¯¹æŠ—ã€‚

**15. India will invest $1.1B to boost development of biologics, biosimilars** â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - å°åº¦æ”¿åºœå·¨é¢æŠ•èµ„ç”Ÿç‰©è¯ä¸ç”Ÿç‰©ç±»ä¼¼è¯ï¼Œæ ‡å¿—å…¶ä»ä»¿åˆ¶è¯å‘ç”Ÿç‰©åˆ¶è¯çš„æˆ˜ç•¥è½¬å‹ã€‚

**3. FDA signals tailored approach to â€˜carefully shepherdâ€™ CAR-T therapy for autoimmune diseases** â­â­â­â­
   - ç±»åˆ«: æ–°è¯ç ”å‘
   - FDAè¡¨æ€æ”¯æŒCAR-Tç–—æ³•å‘è‡ªèº«å…ç–«ç—…é¢†åŸŸæ‹“å±•ï¼Œé¢„ç¤ºç»†èƒç–—æ³•æ–°å‰æ²¿çš„ç›‘ç®¡è·¯å¾„ã€‚

### ğŸ“ åˆ†ç±»æ‘˜è¦

**æ–°è¯ç ”å‘** (Drug R&D): CAR-Tç–—æ³•å‘è‡ªèº«å…ç–«ç—…æ‹“å±•è·FDAæ”¯æŒï¼›è¯ºå’Œè¯ºå¾·ï¼ˆNovo Nordiskï¼‰CagriSemaç»„åˆç–—æ³•åœ¨ç³–å°¿ç—…è¯•éªŒä¸­è¾¾åˆ°ç›®æ ‡ï¼›FDAæˆäºˆEn Carta Diagnosticsè±å§†ç—…æ£€æµ‹è®¾å¤‡çªç ´æ€§è®¾å¤‡è®¤å®šã€‚
**ä¸´åºŠè¯•éªŒ** (Clinical Trials): è¯ºå’Œè¯ºå¾·CagriSemaåœ¨ç³–å°¿ç—…è¯•éªŒä¸­æ˜¾ç¤ºå‡ºä¼˜äºWegovyçš„é™ç³–å’Œå‡é‡æ•ˆæœï¼›è¾‰ç‘ï¼ˆPfizerï¼‰åœ¨è´¢æŠ¥ä¸­æåŠè‚¥èƒ–ç—‡è¯ç‰©çš„ç§¯ææ•°æ®ã€‚

### ğŸ”® æ˜æ—¥å…³æ³¨

å…³æ³¨å®‰è¿›ï¼ˆAmgenï¼‰ä¸FDAå°±Tavneosæ’¤å¸‚è¦æ±‚çš„åç»­è¿›å±•ï¼›ç•™æ„å°åº¦ç”Ÿç‰©åˆ¶è¯æŠ•èµ„è®¡åˆ’çš„å…·ä½“å®æ–½ç»†èŠ‚ï¼›ç›‘æµ‹é¦–æ‰¹10ç§Medicareè°ˆåˆ¤è¯å“ä»·æ ¼ç”Ÿæ•ˆåå¯¹æ‚£è€…å®é™…èŠ‚çœçš„å½±å“è¯„ä¼°ã€‚


---

## æ•°æ®ç»Ÿè®¡

| ç±»åˆ« | æ•°é‡ |
|------|------|
| ç»¼åˆ (ç»¼åˆ) | 44 |
| æ–°è¯ç ”å‘ (Drug R&D) | 34 |
| ç›‘ç®¡å®¡æ‰¹ (Regulatory) | 20 |
| å•†ä¸šåŠ¨æ€ (Business/M&A) | 8 |

---

## ç»¼åˆ | ç»¼åˆ

### ğŸ‡ºğŸ‡¸ FDAâ€™s rare pediatric disease voucher program revived by 2026 government funding bill

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 15:02
- **é‡è¦æ€§**: â­â­â­â­

> By signing a government funding bill that ended a partial shutdown, President Donald Trump has also reauthorized a beloved program meant to speed the development of new drugs for rare childhood diseases.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/fdas-rare-pediatric-disease-voucher-program-revived-2026-government-funding-bill)

---

### ğŸ‡ºğŸ‡¸ Rising Stars: emagineHealth's Barbara Leal lives and works by the mantra of â€˜humans first, professionals secondâ€™

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-02 15:25
- **é‡è¦æ€§**: â­â­â­â­

> In a Q&amp;A for Fierce Pharma Marketingâ€™s â€œRising Starsâ€ series, Leal explained how healthcare and pharma marketing combines the â€œbest of both worldsâ€ for her.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/rising-stars-barbara-leal-lives-and-works-mantra-humans-first-professionals-second)

---

### ğŸ‡ºğŸ‡¸ FDA signals tailored approach to â€˜carefully shepherdâ€™ CAR-T therapy for autoimmune diseases

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 11:17
- **é‡è¦æ€§**: â­â­â­â­

> As the first CAR-T treatment for an autoimmune disease draws ever closer, the FDAâ€™s Vinay Prasad, M.D., and colleagues have signaled a willingness to support the development of these novel cell therapies with a flexible regulatory approach.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/biotech/fda-signals-tailored-approach-carefully-shepherd-car-t-therapy-autoimmune-diseases)

---

### ğŸ‡ºğŸ‡¸ Even with pricing headwinds, Eli Lilly expects sales surge to continue in 2026

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 14:27
- **é‡è¦æ€§**: â­â­

> Eli Lilly said it will be impacted by pricing pressures in 2026 for its juggernaut products Mounjaro and Zepbound. But the company's momentum is such that it still expects revenues to reach between $80 billion and $83 billion, which would be a 25% increase from 2025 sales at the midpoint.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/even-pricing-headwinds-eli-lilly-expects-sales-continue-surge-2026)

---

### ğŸ‡ºğŸ‡¸ AbbVie, hitting record sales on Skyrizi gains, holds its own in growing IBD arena despite J&amp;J competition

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 14:08
- **é‡è¦æ€§**: â­â­

> AbbVie's immunology drug portfolio of Skyrizi, Rinvoq and older Humira contributed $30.4 billion to the company's yearly haul of $61.1 billion.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/abbvie-hitting-record-sales-high-skyrizi-gains-holds-its-own-growing-ibd-arena-despite-jj)

---

### ğŸ‡ºğŸ‡¸ As CEO, Luke Miels wants GSK to be more 'product-centric'

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 09:10
- **é‡è¦æ€§**: â­â­

> In his first investor update as GSKâ€™s CEO, Luke Miels defined a core of his vision for the companyâ€™s next chapter: â€œWe need to be more product-centric as a company.â€

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/ceo-luke-miels-wants-gsk-be-more-product-centric)

---

### ğŸ‡ºğŸ‡¸ Amgen resists FDA request to pull rare disease drug Tavneos from the market

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 07:41
- **é‡è¦æ€§**: â­â­

> Amgen has denied a request by the FDA to voluntarily withdraw its rare disease drug Tavneos from the market, the company said Tuesday as it presented quarterly financial results.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/amgen-resists-fda-request-pull-rare-disease-drug-tavneos-market-0)

---

### ğŸ‡ºğŸ‡¸ India will invest $1.1B to boost development of biologics, biosimilars

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 14:10
- **é‡è¦æ€§**: â­â­

> Long known for manufacturing generics, vaccines and small-molecule drugs, India is attempting to shift its focus, with a big boost from its government. The country will invest 100 billion rupees ($1.1 billion) over the next five years to increase research and production of biologics and biosimilars

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/india-will-invest-11b-boost-development-biologics-biosimilars)

---

### ğŸ‡ºğŸ‡¸ FDA rejects AZ's subQ Saphnelo, but company expects quick turnaround for new approval decision

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 09:01
- **é‡è¦æ€§**: â­â­

> AstraZeneca will have to negotiate what appears to be a minor speed bump in order to gain clearance in the U.S. for its subcutaneous version of lupus treatment Saphnelo. The FDA has rejected AZ's application that would allow patients to self-administer the monoclonal antibody in a prefilled pen. The advancement would give patients a convenient alternative to traveling to a doctor's office for infusions every four weeks.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/fda-gets-under-az-skin-rejection-its-subcutaneous-version-saphnelo)

---

### ğŸ‡ºğŸ‡¸ With FDA rejections, Aquestive's shares go up, while Pharming's go down

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-02 11:15
- **é‡è¦æ€§**: â­â­

> The FDA issued complete response letters to Aquestive Therapeutics and Pharming in recent days, resulting in vastly different reactions from the market.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/fda-rejections-aquestives-shares-go-while-pharmings-go-down)

---

### ğŸ‡ºğŸ‡¸ FDA emphasizes drug ingredients, production pledges as it debuts PreCheck manufacturing program

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-02 10:02
- **é‡è¦æ€§**: â­â­

> Amid an outpouring of industry investments in U.S. drug production, the FDA has launched a new program designed to reduce the complexities involved in setting up domestic manufacturing plants.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/fda-emphasizes-drug-ingredients-production-pledges-it-debuts-precheck-manufacturing-program)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about worries over FDA voucher program, a new U.S. Novo exec, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-04 14:09
- **é‡è¦æ€§**: â­â­

> FDA leaders tried to quell concerns about a controversial new program to fast-track certain drugs at an employee town hall meeting

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/04/novo-obesity-trump-psychedelics-fda-vouchers-switzerland/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about a Pfizer obesity pill, Floridaâ€™s failed drug importation plan, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-03 14:28
- **é‡è¦æ€§**: â­â­

> Pfizer disclosed that an experimental weight loss drug, recently picked up through its acquisition of Metsera, hit its marks in a mid-stage study

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/03/pfizer-obesity-florida-gsk-animals-kennedy-astrazeneca-novarits/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about obesity drug sales, Indiaâ€™s biopharma research push, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-02 14:30
- **é‡è¦æ€§**: â­â­

> The long-held expectation that the global market for obesity drugs would reach $150 billion in the next decade is looking a lot less certain

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/02/obesity-lilly-novo-sanofi-india-pfizer-fda/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Lilly, Repertoire strike $2 billion autoimmune alliance

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 16:03
- **é‡è¦æ€§**: â­â­

> And other biotech news, brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/29/biotech-news-lilly-repertoire-strike-autoimmune-alliance/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ BMS celebrates US soccer legend's shutout against cancer in Breyanzi collab

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 11:20
- **é‡è¦æ€§**: â­

> Bristol Myers Squibb has signed Kasey Keller for a Breyanzi partnership, giving the U.S, Soccer Hall of Famer a platform to discuss how the CD19-directed CAR-T cell therapy blocked the recurrence of his non-Hodgkin lymphoma.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/bristol-myers-celebrates-us-soccer-legends-shutout-against-cancer-breyanzi-ad)

---

### ğŸ‡ºğŸ‡¸ OXB expands BMS partnership to churn out lentiviral vectors for commercial CAR-Ts

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 09:47
- **é‡è¦æ€§**: â­

> OXB, a U.K.-based cell and gene therapy manufacturer, expanded its ongoing partnership with Bristol Myers Squibb to supply lentiviral vectors for the pharma giantâ€™s CAR-T programs.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/oxb-expands-bms-partnership-churn-out-lentiviral-vectors-car-t)

---

### ğŸ‡ºğŸ‡¸ BMS, J&amp;J factor in HCP education on clot-busting mechanism before milvexian data drop

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 09:42
- **é‡è¦æ€§**: â­

> Bristol Myers Squibb and Johnson &amp; Johnson have begun an educational campaign about the factor XIa pathway, laying the groundwork for a launch that could follow phase 3 readouts expected this year.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/bms-jj-factor-physician-education-clot-busting-mechanism-x-factor-readouts)

---

### ğŸ‡ºğŸ‡¸ Novartis CEO projects 2026 growth despite â€˜largest patent expiryâ€™ in company history

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-04 13:40

> Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmakerâ€™s fourth-quarter results start to show the impact of the â€œlargest patent expiryâ€ in its history.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/novartis-ceo-projects-2026-growth-despite-largest-patent-expiry-company-history)

---

### ğŸ‡ºğŸ‡¸ UPDATE: Novo shares plummet on sales, profit warning for '26 as 2 top execs head for the doors

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 13:39

> Novo Nordisk turned in sales and profit growth in 2025 amid an intense obesity market rivalry with Eli Lilly. But investor optimism came to a sudden halt Tuesday as the company warned of significant sales and earnings declines in 2026.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/novo-shares-plummet-sales-profit-warning-26)

---

### ğŸ‡ºğŸ‡¸ Sweden's Nanologica acquires API facility from CDMO Ardena, brings team of 45 on board

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 08:31

> Nanologica, a life sciences company that makes silica-based peptides for the pharmaceutical industry, acquired CDMO Ardenaâ€™s Syntagon manufacturing facility in a stock deal valued at 8.6 million Swedish kroner ($961,000).

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/swedens-nanologica-acquires-ardenas-syntagon-facility-stock-trade-deal)

---

### ğŸ‡ºğŸ‡¸ A 'game of inches': Pfizer channels Al Pacino in World Cancer Day ad

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 12:22

> To stir up support for the fight against cancer, Pfizer has turned to one of the most iconic pep talks of all time.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/pfizer-channels-al-pacino-spirited-world-cancer-day-ad)

---

### ğŸ‡ºğŸ‡¸ HHS launches $100M antiviral prize to develop broad-spectrum therapies

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 14:39

> While the Trump administration may be pivoting away from certain vaccinations, it is pushing for the development of antiviral therapies via the launch of a $100 million antiviral therapy development competition.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/biotech/hhs-launches-100-million-antiviral-prize-develop-broad-spectrum-therapies)

---

### ğŸ‡ºğŸ‡¸ Charles River to close cell therapy CDMO site, lay off 20 staffers

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 12:02

> Charles River Laboratories is continuing its run of layoffs by announcing the closure of its cell therapy contract development and manufacturing organization (CDMO) site in Hanover, Maryland that will cost the company 20 jobs.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/cro/charles-river-close-cell-therapy-cdmo-site-lay-20-staffers)

---

### ğŸ‡ºğŸ‡¸ Merck, lining up post-Keytruda future, touts $70B+ in annual opportunities over next decade

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 11:43

> As top-selling Keytruda inches closer to its 2028 patent cliff, Merck's confidence in sustainable growth for the future is "as high as it's ever been," CEO Robert Davis said on the company's full-year 2025 earnings call.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/merck-confident-post-keytruda-future-70b-opportunity-next-decade-growth-drivers)

---

### ğŸ‡ºğŸ‡¸ Sanofi sanctioned by PMCPA over CEO's 'bold claims' about Pfizer RSV vaccine

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-03 05:34

> A U.K. marketing watchdog has sanctioned Sanofi after ruling its CEO Paul Hudson may have undermined the U.K. governmentâ€™s vaccine program by making â€œbold claimsâ€ about a procurement choice.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/sanofi-sanctioned-over-ceos-bold-claims-about-pfizer-vaccine)

---

### ğŸ‡ºğŸ‡¸ AbbVie has â€˜Love in Mindâ€™ with new migraine educational campaign

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-02 12:11

> With Valentineâ€™s Day coming up, AbbVie has love on the brain. Ahead of the holiday, the Big Pharma has unveiled a new campaign focusing on how migraines can impact romantic relationships.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/abbvie-has-love-mind-new-migraine-educational-campaign)

---

### ğŸ‡ºğŸ‡¸ Thermo Fisher trims Mass. head count with Franklin site closure

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-02-02 11:06

> Thermo Fisher is continuing its recent layoff spree with a fresh round of cuts tied to a site itâ€™s shuttering in Franklin, Massachusetts, which currently employs about 200 people.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/thermo-fisher-trims-massachusetts-headcount-franklin-site-closure)

---

### ğŸ‡ºğŸ‡¸ STAT+: FTC settles lawsuit with Express Scripts over charges it manipulated insulin prices, impeded access

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-04 18:07

> The FTC settled a lawsuit against Express Scripts over allegations that the company artificially inflated the price of insulin and impeded access to treatment.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/04/pbm-cigna-express-scripts-ftc-insulin-settlement-rebates/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pfizer defends data on Metsera candidate

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-04 14:44

> And other biotech news, brought to you by the Readout Newsletter

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/04/biotech-news-pfizer-defends-metsera-data/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Novo Nordisk sees lower sales, profits as Wegovy faces growing competition

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-03 17:38

> Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of Wegovy faces growing competition in the obesity market.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/03/novo-nordisk-lowers-sales-profit-forecast/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pfizer unveils data on Metsera drug

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-03 14:41

> And other biotech news brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/03/biotech-news-pfizer-unveils-data-on-metsera-drug/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pfizer moves forward with its hopes for a monthly obesity drug

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-03 12:22

> Pfizer reported that its newly acquired weight loss drug showed promise as a monthly treatment, though the field is growing increasingly competitive.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/03/pfizer-obesity-weight-loss-drug-monthly-metsera-pf3944-met097/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: As U.S. officials move to reduce animal testing in research, focus may shift to restrictions on imports

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-03 09:30

> The Trump administration is seeking to reduce animal testing in research. Some activists are pushing the administration to suspend primate imports for research purposes entirely.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/03/animal-lab-research-imports-kennedy/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: A play takes on Novoâ€™s myth and money

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-02 14:51

> And more biotech news, brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/02/biotech-news-golden-calf-novo-nordisk-play-theater/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Sanofi is reprimanded by a U.K. trade group for misleading claims about a Pfizer vaccine

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-02 13:47

> Sanofi was criticized by a U.K. trade group, which accused it of making misleading claims about its RSV vaccine and disparaging a rival product from Pfizer.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/02/02/pfizer-sanofi-rsv-vaccine-uk/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Why Bristol Myers Squibb believes a decades-old drug can treat Alzheimerâ€™s

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-02 09:30

> Why Bristol Myers Squibb is banking on a decades-old drug to help secure its future.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/02/bristol-myers-squibb-facing-patent-cliff-big-bet-on-cobenfy/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: As its immunology work draws attention, Sanofi also pushes forward in rare disease

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-02-02 06:00

> An experimental Sanofi drug helped improve the neurological problems seen with a rare disease, as the company plans to seek approval.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/02/02/sanofi-venglustat-gaucher-rare-disease-neurological-symptoms/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Up and down the ladder: The latest comings and goings

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-30 17:06

> From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/30/pharma-biotech-jobs-abbvie-merck-biontech-moderna-takeda-novo/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: New rule would force PBMs to disclose drug rebates and other fees

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-30 15:48

> The proposal would mark a significant change for the secretive PBM industry, which often shields crucial data from its clients.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/30/pbm-drug-rebate-transparency-proposed-rule-department-of-labor/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: AstraZeneca looks to China for obesity drug candidates

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-30 14:36

> And other biotech news brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/30/biotech-news-astrazeneca-china-obesity-drug-candidates/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about TrumpRx questions, drugmakers lowering some prices, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-30 14:35

> Three U.S. senators sent a letter to the HHS Office of Inspector General raising questions about TrumpRx â€” whose structure has yet to be detailed

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/30/trump-telehealth-obesity-pbm-insulin-astrazeneca-china/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: States are the next vaccine battleground

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 17:07

> This is the web edition of STAT's D.C. Diagnosis newsletter.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/29/state-vaccine-mandates-health-care-ice-minnesota-dc-diagnosis-newsletter/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Oz, other officials meet with key senators to push Trumpâ€™s ideas for lower drug prices

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 16:30

> Trump wants lawmakers to force pharma companies to lower their prices, but it's not clear the GOP is on board.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/29/mehmet-oz-senate-finance-committee-meeting-most-favored-nations-drug-pricing/?utm_campaign=rss)

---

## æ–°è¯ç ”å‘ | Drug R&D

### ğŸ‡ºğŸ‡¸ Rare pediatric PRV program reauthorized until 2029 via government funding law

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 18:27
- **é‡è¦æ€§**: â­â­â­â­

> President Donald Trump on Tuesday signed the government funding extension that also reauthorized the FDA's ability to issue rare pediatric priority reviews through 2029, reviving an incentive program that industry has fought to keep. ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/rare-pediatric-prv-program-reauthorized-until-2029-via-government-funding-law/)

---

### ğŸ‡ºğŸ‡¸ Pfizer takes $4.4B charge related to cancer drug in fourth-quarter earnings

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-03 12:51
- **é‡è¦æ€§**: â­â­â­â­

> Pfizer took a write-down on one of its recent high-profile acquisitions while reporting a positive readout from another. The pharma giant said on Tuesday it took a $4.4 billion impairment charge related in part to ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/pfizer-takes-4-4b-charge-related-to-cancer-drug-in-fourth-quarter-earnings/)

---

### ğŸ‡ºğŸ‡¸ AstraZeneca gets CRL for prefilled pen version of lupus drug Saphnelo

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-03 12:03
- **é‡è¦æ€§**: â­â­â­â­

> The FDA has handed AstraZeneca a complete response letter for the subcutaneous prefilled, self-injectable pen of Saphnelo for systemic lupus erythematosus (SLE), a month after the asset gained approval in Europe ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/astrazeneca-gets-crl-for-prefilled-pen-version-of-lupus-drug-saphnelo/)

---

### ğŸ‡ºğŸ‡¸ First 10 Medicare-negotiated drug prices have taken effect: Are seniors really saving money?

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 20:42
- **é‡è¦æ€§**: â­â­â­â­

> The first 10 drugs that underwent government price negotiations in 2023 were projected to save the government billions of dollars. Now, one month since the new pricing took effect, the extent to which those savings ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/first-10-medicare-negotiated-drug-prices-have-taken-effect-are-seniors-really-saving-money/)

---

### ğŸ‡ºğŸ‡¸ Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-05 01:08
- **é‡è¦æ€§**: â­â­

> The offering is one of four biotech IPOs that could price by Friday, and comes during the busiest week for such activity since early last year.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/eikon-biotech-ipo-price-cancer-drugs-2026/811169/)

---

### ğŸ‡ºğŸ‡¸ Trump signs funding bill with PBM reforms, hospital-at-home and telehealth extensions

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-04 17:18
- **é‡è¦æ€§**: â­â­

> The funding package ends a partial government shutdown and enacts several healthcare policies, including preserving telehealth flexibilities in Medicare through 2027.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/trump-signs-legislation-end-partial-government-shutdown-pbm-reform-telehealth-hospital-at-home/811365/)

---

### ğŸ‡ºğŸ‡¸ Lilly soars again as fast-selling weight loss drugs top Wall Street projections

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-04 16:14
- **é‡è¦æ€§**: â­â­

> Despite some angst over pricing pressure for GLP-1 drugs, Lilly&rsquo;s bullish projections surpassed consensus estimates, while combined 2025 sales of Zepbound and Mounjaro eclipsed $36 billion.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/lilly-earnings-guidance-q4-2025-obesity-drugs/811317/)

---

### ğŸ‡ºğŸ‡¸ Earnings roundup: Amgen vs. FDA, Pfizerâ€™s defense and Merckâ€™s $70B-in-sales plan

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-04 14:51
- **é‡è¦æ€§**: â­â­

> Amgen is refusing U.S. regulators&rsquo; request to&nbsp;withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on new obesity drug data, and Merck laid out its post-Keytruda future.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/amgen-pfizer-merck-fda-biotech-earnings-q4-2025/811287/)

---

### ğŸ‡ºğŸ‡¸ FDA launches â€˜PreCheckâ€™ program; AstraZeneca, Acadia drugs set back

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-03 15:11
- **é‡è¦æ€§**: â­â­

> The agency&rsquo;s program will be open to pharmaceutical facilities that align with &ldquo;national priorities.&rdquo; Elsewhere, a self-administered lupus drug was turned back and MeiraGTx picked up another gene therapy.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/fda-precheck-astrazeneca-acadia-reject-meiragtx/811092/)

---

### ğŸ‡ºğŸ‡¸ Novo combination obesity shot meets goal in diabetes trial

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-02 19:00
- **é‡è¦æ€§**: â­â­

> CagriSema&rsquo;s blood sugar and weight reductions exceeded the company&rsquo;s blockbuster Wegovy, yet the drug might still struggle to rival Lilly's Zepbound.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/novo-cagrisema-diabetes-reimagine-study-results/811115/)

---

### ğŸ‡ºğŸ‡¸ Veradermics lands $256M IPO for oral Rogaine

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 14:14
- **é‡è¦æ€§**: â­â­

> Veradermics headed out of the gates with an initial public offering that garnered $256 million in gross proceeds, a bigger-than-expected debut that suggests investors may be hungry for a rebound in biotech listings. Veradermics, which ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/veradermics-lands-256m-ipo-for-oral-rogaine/)

---

### ğŸ‡ºğŸ‡¸ Hims adds Grail's cancer test amid questions about widespread use

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 14:00
- **é‡è¦æ€§**: â­â­

> Hims &amp; Hers is bringing Grail's cancer test to its consumer health platform, marking a significant step toward mass adoption of a technology that's shown progress while remaining under scientific debate. Grail, a pioneer in ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/hims-adds-grails-cancer-test-amid-questions-about-widespread-use/)

---

### ğŸ‡ºğŸ‡¸ Novartis says generics to erode $4B from 2026 sales

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 12:44
- **é‡è¦æ€§**: â­â­

> Novartis said further generic erosion of three blockbuster medicines, including its top-selling heart failure drug Entresto, will leave a $4 billion hole in its sales this year. Generic competition started to make a mark in ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/novartis-says-generics-to-erode-4b-from-2026-sales/)

---

### ğŸ‡ºğŸ‡¸ FDA seeks withdrawal of Amgen's Tavneos, but company says it won't pull drug

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 00:48
- **é‡è¦æ€§**: â­â­

> Several years of questions about Amgen's rare disease treatment Tavneos have reached a climax after the FDA asked the company to pull the drug from the market, and Amgen said it has no plans to ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/fda-seeks-withdrawal-of-amgens-tavneos-company-says-it-wont-pull-drug/)

---

### ğŸ‡ºğŸ‡¸ UKâ€™s health department expected to spend Â£1B in pharma trade deal with US

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 00:01
- **é‡è¦æ€§**: â­â­

> The UK's drug pricing deal with the White House is expected to cost Â£1 billion between 2026 and 2029, according to a letter from the country's science minister. The letter was published Wednesday morning by ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/uks-health-department-expected-to-spend-1b-in-pharma-trade-deal-with-us/)

---

### ğŸ‡ºğŸ‡¸ What's driving health tech M&A

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-03 16:28
- **é‡è¦æ€§**: â­â­

> The past week saw a flurry of health tech acquisitions (we counted at least five!). Part of the rush of activity is seasonal â€” the end of the year often serves as a ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/whats-driving-health-tech-ma/)

---

### ğŸ‡ºğŸ‡¸ China startup AccurEdit raises $75M for gene editing therapies

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-03 16:13
- **é‡è¦æ€§**: â­â­

> AccurEdit Therapeutics, a startup based in Suzhou, China, has raised $75 million in Series A funding to advance its growing pipeline of CRISPR-based medicines â€” among the largest rounds on record for a Chinese gene editing ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/china-startup-accuredit-raises-75m-for-gene-editing-therapies/)

---

### ğŸ‡ºğŸ‡¸ Ultragenyx unwraps data that may be central to its gene therapy resubmission

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-03 13:00
- **é‡è¦æ€§**: â­â­

> Ultragenyx outlined new data on Tuesday that it hopes will convince the FDA to approve its recently resubmitted rare disease gene therapy. Among 17 patients with Sanfilippo syndrome type A who received the therapy, cognition ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/ultragenyx-unwraps-data-that-may-be-central-to-its-gene-therapy-resubmission/)

---

### ğŸ‡ºğŸ‡¸ Updated: Do Pfizerâ€™s monthly GLP-1 data justify Metseraâ€™s $10B price tag?

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-03 12:30
- **é‡è¦æ€§**: â­â­

> Pfizer said Tuesday that the monthly injection that was one of the cornerstones of its $10 billion buyout of Metsera allowed obesity patients to lose up to 10.5% of their weight, on ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/pfizers-metsera-originated-monthly-glp-1-cuts-weight-by-10-5-at-six-months/)

---

### ğŸ‡ºğŸ‡¸ Pfizer dips on new data for obesity drug acquired in $10B deal

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-03 17:01
- **é‡è¦æ€§**: â­

> A long-acting shot Pfizer got through a buyout of Metsera appeared &ldquo;slightly inferior&rdquo; to Lilly&rsquo;s market-leading Zepbound in a Phase 2 trial, one analyst said.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/pfizer-obesity-metsera-phase-2-results-GLP1-monthly-shot/811201/)

---

### ğŸ‡ºğŸ‡¸ Novo shares tumble by double digits on grim sales outlook

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-04 16:55

> In contrast to Lilly&rsquo;s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13% decline in 2026 profits.&nbsp;

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/novo-nordisk-2025-earnings-2026-outlook/811318/)

---

### ğŸ‡ºğŸ‡¸ Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-02 17:12

> The drug, which has suffered multiple setbacks over the years, could finally reach the market as a treatment for a form of Gaucher disease.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/sanofi-venglustat-gaucher-fabry-study-results/811113/)

---

### ğŸ‡ºğŸ‡¸ GSK walks away from pioneering Wave RNA editing drug

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-02-02 13:31

> Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because Wave is better suited to quickly advance a rare disease therapy.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/wave-gsk-reacquire-rna-editing-drug-aatd/811067/)

---

### ğŸ‡ºğŸ‡¸ FTC settles insulin lawsuit with Express Scripts

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 20:49

> The FTC has settled with Express Scripts over its use of insulin rebates, securing an agreement that stretches across almost every corner of the company's business model. The commission and Express Scripts

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/ftc-settles-insulin-lawsuit-with-express-scripts/)

---

### ğŸ‡ºğŸ‡¸ AbbVie says immunology blockbusters will be 'main drivers' of growth post-Humira

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 20:40

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/abbvie-says-immunology-blockbusters-will-be-main-drivers-of-growth-post-humira/)

---

### ğŸ‡ºğŸ‡¸ GSKâ€™s new CEO eyes more dealmaking, intense pipeline inspection

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 15:01

> GSK CEO Luke Miels laid out the drugmakerâ€™s vision for how it will meet its 2031 sales forecast and address the upcoming patent cliff for its blockbuster HIV drug dolutegravir. â€œWe need ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/gsks-new-ceo-eyes-more-dealmaking-intense-pipeline-inspection/)

---

### ğŸ‡ºğŸ‡¸ Midi Health raises $100M as it plans expansion into urgent care, research

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 14:00

> Health techâ€™s latest unicorn is Midi Health, a womenâ€™s health startup launched during the pandemic that has since expanded into broader virtual care with a recent focus on longevity. The startup hit ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/midi-health-raises-100m-as-it-plans-expansion-into-urgent-care-research/)

---

### ğŸ‡ºğŸ‡¸ Lilly beats sales forecasts, plots major growth in 2026 in stark contrast to Novo

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 12:10

> Eli Lilly surpassed analysts' expectations for 2025 and fourth-quarter revenues on Wednesday morning, and anticipates a large increase in revenue this year. It marks a sharp juxtaposition to its main rival Novo Nordisk, which expects ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/lilly-beats-sales-forecasts-plots-major-growth-in-2026-in-stark-contrast-to-novo/)

---

### ğŸ‡ºğŸ‡¸ Updated: Embattled Novo Nordisk considers buying a monthly GLP-1, unveils pipeline cuts

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-04 10:55

> Novo Nordisk is looking into acquiring or developing a long-acting GLP-1 drug that could compete with Pfizer's monthly obesity shot. It has also cut a handful of drugs from its pipeline, so it certainly has ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/embattled-novo-nordisk-considers-buying-a-monthly-glp-1-to-bolster-portfolio/)

---

### ğŸ‡ºğŸ‡¸ Novo expects sales to fall in 2026, triggering selloff

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-03 20:07

> Novo Nordisk expects its sales to shrink by at least 5% this year, citing negative pricing dynamics, including its deal with the US government. The Danish pharma said in its

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/novo-expects-sales-to-fall-in-2026-triggering-selloff/)

---

### ğŸ‡ºğŸ‡¸ 'Turning around the Titanic': How the incoming PBM reforms will transform CMS

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-03 19:34

> The Centers for Medicare and Medicaid Services has never played a significant role in regulating pharmacy benefit managers, the middlemen that have historically relied on high drug prices for profits. But the government spending package ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/turning-around-the-titanic-how-the-incoming-pbm-reforms-will-transform-cms/)

---

### ğŸ‡ºğŸ‡¸ Daiichi ends work on an ADC; Layoffs at GSK's R&D unit

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-03 15:30

> Plus, news about Acadia Pharmaceuticals, Eli Lilly, PepLib Biotech, MeiraGTx, ZipBio, SantÃ© Ventures, Adlai Nortye, NMD Pharma, Eton Pharmaceuticals, vTv Therapeutics and Newsoara: âœ‚ï¸ Daiichi Sankyo culls next-gen ADC: Citing a strategic portfolio review ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/daiichi-ends-work-on-an-adc-layoffs-at-gsks-rd-unit/)

---

### ğŸ‡ºğŸ‡¸ Menlo and a16z back AI scientist startup Phylo

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-03 12:00

> Within days of defending their PhDs last year, two Stanford University researchers incorporated their own startup, betting they could build a business around their AI system that handles scientific tasks. The Bay Area startup, called ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/menlo-and-a16z-back-ai-scientist-startup-phylo/)

---

### ğŸ‡ºğŸ‡¸ Carbon Health files for bankruptcy, seeking to sell or restructure

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-02-02 21:22

> Carbon Health has filed for bankruptcy protection and is seeking to restructure or sell itself, the urgent and primary care startup said Monday. The company voluntarily filed for Chapter 11 in the US Bankruptcy Court ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/carbon-health-files-for-bankruptcy-seeking-to-sell-or-restructure/)

---

## ç›‘ç®¡å®¡æ‰¹ | Regulatory

### ğŸ‡ºğŸ‡¸ Understanding the Risks of Compounded Drugs

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-04 20:18
- **é‡è¦æ€§**: â­â­â­â­

> Compounded drugs are not FDA-approved. This means the agency does not verify their safety, effectiveness or quality before they are marketed. Learn more.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs)

---

### ğŸ‡ºğŸ‡¸ FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-04 18:35
- **é‡è¦æ€§**: â­â­â­â­

> On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cel

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-bortezomib-lenalidomide-and-dexamethasone-newly)

---

### ğŸ‡ºğŸ‡¸ PDUFA VIII: Fiscal Years 2028 â€“ 2032

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-04 22:31
- **é‡è¦æ€§**: â­â­

> Information related to FDAâ€™s preparation for the seventh reauthorization of PDUFA.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/prescription-drug-user-fee-amendments/pdufa-viii-fiscal-years-2028-2032)

---

### ğŸ‡ºğŸ‡¸ What's New Related to Drugs

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-04 21:46
- **é‡è¦æ€§**: â­â­

> Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs)

---

### ğŸ‡ºğŸ‡¸ Drug Trials Snapshots

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-04 21:41
- **é‡è¦æ€§**: â­â­

> Drug Trials Snapshots: breaking down the what, how and why. Drug Trials Snapshots is part of an overall FDA effort to make demographic data more available and transparent.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots)

---

### ğŸ‡ºğŸ‡¸ About CDER Small Business and Industry Assistance (SBIA)

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-04 16:30
- **é‡è¦æ€§**: â­â­

> CDER Small Business and Industry Assistance (SBIA) helps small pharmaceutical business and industry navigate the wealth of information that FDA offers, and provides assistance in understanding the regulation of human drug products.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/about-cder-small-business-and-industry-assistance-sbia)

---

### ğŸ‡ºğŸ‡¸ Novel Drug Approvals for 2025

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-04 21:41

> Innovative drugs often mean new treatment options for patients and advances in health care for the American public.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)

---

### ğŸ‡ºğŸ‡¸ Drug Trials Snapshots: WAYRILZ

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-04 21:40

> Drug Trials Snapshots: WAYRILZ

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-wayrilz)

---

### ğŸ‡ºğŸ‡¸ Withdrawn and Expired Guidances | Drugs

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-04 18:54

> Withdrawn and Expired Guidances | Drugs

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/guidances-drugs/withdrawn-and-expired-guidances-drugs)

---

### ğŸ‡ºğŸ‡¸ Generic Drug User Fee Amendments

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-04 18:50

> This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments)

---

### ğŸ‡ºğŸ‡¸ GDUFA Type II API DMF Payment Receipts Report

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-04 18:46

> GDUFA Type II API DMF Payment Receipts Report

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/fda-user-fee-programs/gdufa-type-ii-api-dmf-payment-receipts-report)

---

### ğŸ‡ºğŸ‡¸ Generic Drug Facilities, Sites and Organization Lists

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-04 18:45

> Generic Drug Facilities, Sites and Organization Lists

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists)

---

### ğŸ‡ºğŸ‡¸ Compounding Quality Center of Excellence | Instructor-Led Trainings

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-04 18:30

> The Compounding Quality Center of Excellenceâ€™s free in-person training programs target outsourcing facility staff and offer continuing education credits. The training will open for state regulators and pharmacy compounders if space is available.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/compounding-quality-center-excellence/compounding-quality-center-excellence-instructor-led-trainings)

---

### ğŸ‡ºğŸ‡¸ Drug Trials Snapshots: REDEMPLO

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-04 16:54

> Drug Trials Snapshots: REDEMPLO

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-redemplo)

---

### ğŸ‡ºğŸ‡¸ Stay Informed about Small Business

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-04 16:51

> Stay Informed about Small Business

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/stay-informed-about-small-business)

---

### ğŸ‡ºğŸ‡¸ CDER Small Business and Industry Assistance (SBIA) Learn

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-04 16:49

> SBIA Learn offers a variety of multimedia resources to provide information that is comprehensive, interactive, and easily accessible to small pharmaceutical business and industry.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/cder-small-business-and-industry-assistance-sbia-learn)

---

### ğŸ‡ºğŸ‡¸ Health Fraud Scams

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-04 16:42

> Learn how to spot health fraud and avoid it.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/consumers/health-fraud-scams)

---

### ğŸ‡ºğŸ‡¸ Drug Trials Snapshots: LEROCHOL

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-04 16:36

> Drug Trials Snapshots: LEROCHOL

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-lerochol)

---

### ğŸ‡ºğŸ‡¸ CDER Small Business & Industry Assistance (SBIA)

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-04 16:12

> A Comprehensive Resource for Information on Human Drug Development in Regulation

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/development-approval-process-drugs/cder-small-business-industry-assistance-sbia)

---

### ğŸ‡ºğŸ‡¸ Drug Trials Snapshots: REDEMPLO

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-02-04 16:12

> Drug Trials Snapshots: REDEMPLO

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-redemplo-0)

---

## å•†ä¸šåŠ¨æ€ | Business/M&A

### ğŸ‡ºğŸ‡¸ En Carta Diagnosticsâ€™ EC Pocket Lyme test receives FDA Breakthrough Device Designation

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-02 14:18
- **é‡è¦æ€§**: â­â­â­â­

> The US sees around 476,000 new Lyme cases every year

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/en-carta-diagnostics-ec-pocket-lyme-test-receives-fda-breakthrough-device-designation/)

---

### ğŸ‡ºğŸ‡¸ IBSA UK&I launches Perovial for the treatment of acute Peyronieâ€™s disease

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-03 12:32
- **é‡è¦æ€§**: â­â­

> Perovial is the first ever hyaluronic acid injectable treatment to be licensed for acute Peyronieâ€™s disease

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/ibsa-uki-launches-perovial-for-the-treatment-of-acute-peyronies-disease/)

---

### ğŸ‡ºğŸ‡¸ CERo reports encouraging early data from phase 1 trial of CERâ€‘1236

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-29 10:59
- **é‡è¦æ€§**: â­

> CERâ€‘T therapy shows initial safety signals and prompts protocol expansion

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/cero-reports-encouraging-early-data-from-phase-1-trial-of-cer-1236/)

---

### ğŸ‡ºğŸ‡¸ ENA Respiratory begins dosing in phase 2 study of INNAâ€‘051 nasal spray

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-29 10:44
- **é‡è¦æ€§**: â­

> Trial to assess whether onceâ€‘weekly treatment can reduce symptomatic viral respiratory infections

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/ena-respiratory-begins-dosing-in-phase-2-study-of-inna-051-nasal-spray/)

---

### ğŸ‡ºğŸ‡¸ Thomas Farrell

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-04 09:48

> NanoSyrinx has appointed Thomas Farrell as CEO and Director

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/appointments/thomas-farrell/)

---

### ğŸ‡ºğŸ‡¸ Ahmed Moussa

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-04 09:42

> Ahmed Moussa is the new Sanofi Country Lead for UK &#038; Ireland

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/appointments/ahmed-moussa/)

---

### ğŸ‡ºğŸ‡¸ Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-03 12:43

> The company will initially develop a vaccine to tackle colorectal and pancreatic cancers

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/kahimmune-therapeutics-enters-licensing-agreement-with-gustave-roussy-and-satt-paris-saclay/)

---

### ğŸ‡ºğŸ‡¸ ALKâ€™s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-02-02 14:08

> Anaphylaxis is the most serious type of allergic reaction and occurs more commonly in boys

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/alks-eurneffy-receives-positive-chmp-opinion-for-emergency-anaphylaxis-treatment-in-children/)

---


---

*Generated by Pharma Daily - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ*

*2026-02-05 04:14:07*